| Table 2. Synthetic agents utilize for PCOS treatment. | ||||
| Category | Name of Drug | MOA | Side Effects | References |
|---|---|---|---|---|
| Insulin Sensitizers | Metformin | Promote the absorption of glucose in intestine, ↓ the liver’s synthesis of glucose, ↓ the absorption of glucose in the intestines, and ↓both fasting and post-meal blood glucose levels. | Diarrhea, Flatulence, bloating, anorexia, stomach discomfort, metallic taste in mouth, and nausea | Mathur et al., 2008; Diamanti-Kandarakis et al., 2010; Lashen, 2010; Johnson, 2014; Dumitrescu et al., 2015; Ryssdal et al., 2023 |
| TZDs | Pioglitazone | ↓ release of fatty acids, ↓ TNF α-induced inhibition of insulin action | Congestive heart failure | Glintborg & Andersen, 2010; Du et al., 2012; Madnani et al., 2013; Piątkowska-Chmiel et al., 2022) |
| Rosiglitazone | ↑ transcription of PPAR-γ and ↑ Insulin-induced target cell response | Peripheral Edema | ||
| DPP-4 inhibitors | Sitagliptin | ↑ incretin levels, ↓ DPP-4 enzyme and ↑ synthesis of insulin by beta cells of pancreas | Angiopathic Edema | Ferjan et al., 2018; Modarres et al., 2023 |
| Linagliptin and Alogliptin | Weight increase and hyperinsulinemia | Headache, upper respiratory tract infection | ||
| GLP-1 agonists | Exenatide | Weight loss, lipogenesis | Injection site reaction | Bednarz et al., 2022 |
| SGLT-2 Inhibitors | Empagliflozin | Obesity, androgen excess, Hyperinsulinemia | Infections of urinary system and female genital mycotic | Cassidy-Vu et al., 2016; Marinkovic-Radosevic et al., 2021 |
| Dapagliflozin | ↓ Renal glucose threshold, ↓ glucose reabsorption from renal tubules | Elevated urination | Elkind-Hirsch et al., 2021 | |
| Canagliflozin | ↓intestinal reabsorption of glucose, ↑ incretin secretion | Urinary tract disease, moderate diarrhea, nausea, and a female genital mycotic infection | Zhang et al., 2022 | |
| Anti-estrogen | Clomiphene Citrate | Prevents the hypothalamus-pituitary axis from responding to endogenous estrogen in the blood by blocking estrogenic hypothalamic receptors. This, in turn, causes the anterior pituitary to produce FSH in response to changes in GnRH pulsatility. | Impaired vision, nausea and vomiting, breast pain, ovarian enlargement, and abdominal-pelvic discomfort/distention/bloating | Kamath & George, 2011 |
| Aromatase inhibitor |
Letrozole | The enzyme aromatase, which helps turn androgens into estrogens, is competitively inhibited by nonsteroidal compounds. | Headache, hot flashes, asthenia, hypercholesterolemia, edema, bone pain, flushing | Pajai et al., 2022 |
| Antiandrogens | Flutamide | reduces androgen synthesis through the restoration of ovulation | Hepatocellular Toxicity | De Leo et al., 1998; Ryan et al., 2018 |
| Finasteride | impede the activation of DHT by 5 alpha reductases, hence diminishing the impact of androgens. | Sexual dysfunction, depression, erectile dysfunction, loss of libido | Moghetti et al., 1994; Traish, 2020 |
|
| Spironolactone | Partial blockage of testosterone production, aromatase stimulation, and androgen receptor blockade | Intermenstrual bleeding | Zulian et al., 2005; Sabbadin et al., 2016) |
|